Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinibThe FDA also provided positive feedback on the proposed key clinical and regulatory requirements of Oncternal's development program for zilovertamab in MCLGlobal registrational Study ZILO-301 is expected to be initiated in the second quarter of 2022Oncternal Therapeutics will host a conference call today at 4:30 p.m. ET to provide further details SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the d
